Literature DB >> 10867311

Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study.

J Addington1, D Addington.   

Abstract

In our previous study we demonstrated that, in 80 schizophrenia subjects, verbal ability, verbal memory and executive functioning were significantly associated with social problem solving. The objective of this present study was to assess the longitudinal stability of the relationship between social and neurocognitive functioning in schizophrenia. This 2.5 year longitudinal cohort study re-assessed community functioning, social problem solving and symptoms in 65 of the 80 original subjects to determine the predictive ability of neurocognitive functioning. Neurocognition was not re-assessed at this follow-up. Positive and negative symptoms were assessed with the Positive and Negative Syndrome Scale. Social functioning was assessed using the Social Functioning Scale, the Quality of Life Scale, and the Assessment of Interpersonal Problem-Solving Skills (AIPSS). Verbal ability, verbal memory and vigilance were significant predictors of social problem solving as assessed by the AIPSS. Results suggest that the association between neurocognition and social functioning remains consistent over time.

Entities:  

Mesh:

Year:  2000        PMID: 10867311     DOI: 10.1016/s0920-9964(99)00160-7

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  56 in total

1.  [Early dementia as primary syndrome of schizophrenia].

Authors:  F U Lang; R Klug; M Kunath; C Palm; I Uttner; M Jäger
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

2.  Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits.

Authors:  Joseph Ventura; April D Thames; Rachel C Wood; Lisa H Guzik; Gerhard S Hellemann
Journal:  Schizophr Res       Date:  2010-06-25       Impact factor: 4.939

3.  Relationships Between Working Alliance and Outcomes in Group Therapy for People Diagnosed with Schizophrenia.

Authors:  Danielle M Beaudette; Lisa N Cruz; Alicia Lukachko; Matthew Roché; Steven M Silverstein
Journal:  Psychosis       Date:  2020-06-16

4.  Cognitive predictors of social functioning improvements following cognitive remediation for schizophrenia.

Authors:  Clare Reeder; Nicola Smedley; Kate Butt; Diana Bogner; Til Wykes
Journal:  Schizophr Bull       Date:  2006-08-10       Impact factor: 9.306

5.  Social/communication skills, cognition, and vocational functioning in schizophrenia.

Authors:  Dwight Dickinson; Alan S Bellack; James M Gold
Journal:  Schizophr Bull       Date:  2006-12-12       Impact factor: 9.306

6.  The role of neurocognition and social context in predicting community functioning among formerly homeless seriously mentally ill persons.

Authors:  Russell K Schutt; Larry J Seidman; Brina Caplan; Anna Martsinkiv; Stephen M Goldfinger
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

7.  Clinical and demographic correlates of stigma in first-episode psychosis: the impact of duration of untreated psychosis.

Authors:  K T Mueser; N R DeTore; M A Kredlow; M L Bourgeois; D L Penn; K Hintz
Journal:  Acta Psychiatr Scand       Date:  2019-10-11       Impact factor: 6.392

8.  Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches.

Authors:  Keith H Nuechterlein; Joseph Ventura; Kenneth L Subotnik; Jacqueline N Hayata; Alice Medalia; Morris D Bell
Journal:  Am J Psychiatr Rehabil       Date:  2014-07

9.  Symptom correlates of static and dynamic facial affect processing in schizophrenia: evidence of a double dissociation?

Authors:  Patrick J Johnston; Peter G Enticott; Angela K Mayes; Kate E Hoy; Sally E Herring; Paul B Fitzgerald
Journal:  Schizophr Bull       Date:  2008-10-26       Impact factor: 9.306

10.  Should cognitive impairment be included in the diagnostic criteria for schizophrenia?

Authors:  Richard S E Keefe
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.